Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts broadly favor Compass Therapeutics: Sixteen analysts give the stock a consensus “Moderate Buy” rating, including 13 buys and one strong buy. The average 12-month price target is $11.77.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 68.43% of CMPX, with several firms recently initiating or increasing positions.
• Recent performance remains weak: Shares opened at $2.21, near the 50-day moving average and well below the $6.88 one-year high. The company also missed its latest quarterly EPS estimate, reporting a $0.13 loss versus the expected $0.11 loss.

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the sixteen analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $11.7692.

Several brokerages have commented on CMPX. Stifel Nicolaus set a $6.00 price target on shares of Compass Therapeutics in a research report on Monday, June 1st. LADENBURG THALM/SH SH initiated coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They issued a "buy" rating and a $5.00 price objective on the stock. Piper Sandler lifted their target price on Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Wall Street Zen lowered Compass Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research report on Friday, July 17th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC purchased a new stake in shares of Compass Therapeutics during the 1st quarter worth $28,000. Russell Investments Group Ltd. boosted its holdings in Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock valued at $27,000 after purchasing an additional 7,592 shares in the last quarter. Xponance LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at $55,000. CIBC Bancorp USA Inc. purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at $37,000. Finally, PNC Financial Services Group Inc. raised its stake in Compass Therapeutics by 2,572.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 11,038 shares of the company's stock worth $58,000 after acquiring an additional 10,625 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $2.21 on Wednesday. The firm has a market capitalization of $398.00 million, a PE ratio of -5.52 and a beta of 0.95. Compass Therapeutics has a 1 year low of $1.61 and a 1 year high of $6.88. The firm's 50-day moving average is $2.22 and its two-hundred day moving average is $3.24.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Analysts expect that Compass Therapeutics will post -0.47 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.